Liquid Biopsies: The Next Shift in Diagnostics

The shift away from tissue biopsies towards liquid biopsies feels like a real innovation. How will that play out and what are the consequences for labs?

It's not just an innovation; it is a paradigm shift in precision medicine, particularly in oncology. Currently, liquid biopsies are largely acting as an adjunct to tissue biopsies, but liquid biopsies will become the standard of care for therapy selection, monitoring minimal residual disease (MRD), and tracking therapy resistance in real-time. Simply put, because blood can be drawn frequently, longitudinal tracking of a tumour's molecular profile becomes a reality – something impossible with invasive, single-timepoint tissue biopsies.

And remember, in cases where tumours are inaccessible, or when a patient is too compromised for surgery, liquid biopsies will completely replace tissue sampling. And of course, as sensitivity improves, the Holy Grail of multi-cancer early detection (MCED) screening via routine blood work will become a primary diagnostic tool.

So for labs there's a strategic pivot ahead – workflows that pivot toward handling plasma. They'll need specialised collection tubes that stabilise cfDNA during transit, as well as distinct, highly optimised nucleic acid extraction kits designed specifically for fragmented, low-yield circulating DNA. For Celtic Molecular Diagnostics and our partners, this is a massive opportunity and we look forward to being drivers on the journey.